Clinical trial

Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

NCT01332370

Study summary

ClinicalTrials.gov

Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Rosiglitazone + Metformin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Sitagliptin + Metformin Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-12-01

PhaseN/A

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Rosiglitazone + MetforminDRUG

Sitagliptin + MetforminDRUG

Sponsors & collaborators

GlaxoSmithKlinelead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01332370 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.